MedTrace Logo

AZD8330 First Time in Man in Patients With Advanced Malignancies

NCT00454090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2011-08-24

No results posted yet for this study

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Conditions

Interventions

DRUG

AZD8330

oral tablet

Sponsors & Collaborators

Principal Investigators

  • Emerging Oncology Medical Science Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-10-31
Completion
2011-03-31

Countries

  • United States
  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454090 on ClinicalTrials.gov